Disc Medicine Reports Strong Anemia Response Rates in Myelofibrosis Trial Ahead of EHA 2026
Event summary
- Disc Medicine to present oral data from RALLY-MF Phase 2 trial of DISC-0974 in myelofibrosis patients at EHA 2026 Congress.
- Initial results show 54% major response rate in non-transfusion dependent cohort, 67% in lightly transfused, and 50% in heavily transfused.
- Additional abstracts on bitopertin in EPP and DISC-3405 in polycythemia vera to be presented.
- Corporate update conference call scheduled for June 15, 2026.
The big picture
Disc Medicine's upcoming presentations at EHA 2026 highlight its focus on addressing unmet needs in hematologic diseases. The strong initial data from the RALLY-MF trial positions DISC-0974 as a potential key player in treating anemia associated with myelofibrosis. The company's multi-pronged approach across different hematologic conditions underscores its strategic aim to build a robust pipeline in a highly specialized therapeutic area.
What we're watching
- Clinical Efficacy
- How sustained response rates in myelofibrosis patients will impact DISC-0974's development trajectory.
- Regulatory Pathway
- Whether the upcoming APOLLO Phase 3 trial readout for bitopertin will meet expectations.
- Market Positioning
- The pace at which Disc Medicine can differentiate its portfolio in the competitive hematology space.